Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Impact · against what's priced in

The news is a positive catalyst for PHIO as it provides concrete evidence of efficacy in early trials and clears a critical regulatory hurdle for future pivotal studies. The FDA's acceptance of the toxicology protocol and the reported complete responses in cSCC patients significantly advance the clinical validity of PH-762.

PHIO+0.70

No priced-in read yet